Recombinant Bacille Calmette–Guérin for Immunotherapy in Nonmuscle Invasive Bladder Cancer.
10.22465/kjuo.2016.14.3.109
- Author:
Subin JIN
1
;
Young Mi WHANG
;
In Ho CHANG
Author Information
1. Department of Urology, Chung-Ang University Hospital, Seoul, Korea. caucih@cau.ac.kr
- Publication Type:Review
- Keywords:
BCG vaccine;
Urinary bladder neoplasms;
Immunotherapy
- MeSH:
Administration, Intravesical;
BCG Vaccine;
Humans;
Immunotherapy*;
Mycobacterium bovis;
Urinary Bladder Neoplasms*;
Urinary Bladder*
- From:Korean Journal of Urological Oncology
2016;14(3):109-117
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Intravesical instillation of Mycobacterium bovis bacille Calmette–Guérin (BCG) has been used for treating nonmuscle invasive bladder cancer as the forefront of immunotherapy, but BCG is ineffective in approximately 30–40% of cases and disease recurs in up to 50% of patients. Recently BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, and the genetic control of these mycobacteria is advanced in the search for less toxic and more potent therapeutic agents for bladder cancer immunotherapy. We will discuss current advances in recombinant BCG construction, research, and future directions.
